Table 14.
Association Between Plasma Ceramides and Change in Coronary Artery Diameter in Study Participants With Endothelium‐Dependent Vascular Dysfunction (CFR >2)
| Adjusted model | Standardized β coefficient | P value |
|---|---|---|
| 1 | ||
| Age | 0.44 | 0.032 |
| Sex | 10.20 | 0.033 |
| Plasma ceramides 18:0/24:0 | −428.86 | 0.016 |
| 2 | ||
| Age | 0.53 | 0.011 |
| Sex | 9.25 | 0.056 |
| Hypertension | −4.68 | 0.262 |
| Diabetes | 9.44 | 0.149 |
| Hyperlipidemia | −5.12 | 0.378 |
| Lipid‐lowering drug use | −6.59 | 0.242 |
| Plasma ceramides 18:0/24:0 | −418.38 | 0.020 |
| 3 | ||
| Age | 0.45 | 0.031 |
| Sex | 9.11 | 0.072 |
| Hypertension | −3.69 | 0.389 |
| Diabetes | 10.28 | 0.149 |
| Hyperlipidemia | −6.61 | 0.275 |
| Lipid‐lowering drug use | −2.53 | 0.676 |
| LDL cholesterol | 0.59 | 0.017 |
| Non‐HDL cholesterol | −0.51 | 0.020 |
| Plasma ceramides 18:0/24:0 | −322.55 | 0.084 |
HDL indicates high‐density lipoprotein; and LDL, low‐density lipoprotein.